Recombinant Human Eukaryotic translation initiation factor 4 gamma 1 (EIF4G1), partial

Code CSB-EP007568HU
MSDS
Size $224
Order now
Image
  • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity
Greater than 90% as determined by SDS-PAGE.
Target Names
EIF4G1
Uniprot No.
Research Area
Immunology
Alternative Names
DKFZp686A1451; eIF 4 gamma 1; eIF 4G 1; eIF 4G1; eIF-4-gamma 1; eIF-4G 1; eIF-4G1; EIF4 gamma; EIF4F; EIF4G; EIF4G1; EIF4GI; Eukaryotic translation initiation factor 4 gamma 1; IF4G1_HUMAN; p220
Species
Homo sapiens (Human)
Source
E.coli
Expression Region
1250-1599aa
Target Protein Sequence
IEEYLHLNDMKEAVQCVQELASPSLLFIFVRHGVESTLERSAIAREHMGQLLHQLLCAGHLSTAQYYQGLYEILELAEDMEIDIPHVWLYLAELVTPILQEGGVPMGELFREITKPLRPLGKAASLLLEILGLLCKSMGPKKVGTLWREAGLSWKEFLPEGQDIGAFVAEQKVEYTLGEESEAPGQRALPSEELNRQLEKLLKEGSSNQRVFDWIEANLSEQQIVSNTLVRALMTAVCYSAIIFETPLRVDVAVLKARAKLLQKYLCDEQKELQALYALQALVVTLEQPPNLLRMFFDALYDEDVVKEDAFYSWESSKDPAEQQGKGVALKSVTAFFKWLREAEEESDHN
Note: The complete sequence including tag sequence, target protein sequence and linker sequence could be provided upon request.
Mol. Weight
66.6kDa
Protein Length
Partial
Tag Info
N-terminal GST-tagged
Form
Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer
If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting and FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA
Please contact us to get it.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Component of the protein complex eIF4F, which is involved in the recognition of the mRNA cap, ATP-dependent unwinding of 5'-terminal secondary structure and recruitment of mRNA to the ribosome. As a member of the eIF4F complex, required for endoplasmic reticulum stress-induced ATF4 mRNA translation.
Gene References into Functions
  1. The polymorphism of the rs200221361 may have no association with the occurrence of Parkinson disease in Uygur and Han people of Xinjiang. PMID: 29718834
  2. Epstein-Barr Virus protein EB2 first is recruited to the mRNA cap structure in the nucleus and then interacts with the proteins eIF4G and PABP to enhance the initiation step of translation. PMID: 29142127
  3. EIF4G1 overexpression is associated with non-small cell lung cancers. PMID: 27003362
  4. High EIF4G expression is associated with malignant peripheral nerve sheath tumors and vestibular schwannomas. PMID: 26951381
  5. The study indicates that the EIF4G1 mutation is rare in Taiwan, which is consistent with other reports from Asia. Ethnicity could have a great influence on EIF4G1 in Parkinson's disease. PMID: 26490695
  6. the IRES of encephalomyocarditis virus (EMCV) interacts with the HEAT-1 domain of eukaryotic initiation factor 4G (eIF4G). PMID: 27525590
  7. EIF4G1 mutations are not related to Parkinson's disease PMID: 26022768
  8. VPS35 D620N and EIF4G1 R1205H mutations are not a common cause of Parkinson disease in the Greek population. PMID: 26300542
  9. EIF4GI shares this activity and also interacts with eIF1. PMID: 25738462
  10. EIF4G1 is neither a strong nor a common risk factor for Parkinson's disease: evidence from large European cohorts. PMID: 25368108
  11. This study therefore implicates c-Myc as a potential regulator of the cancer-promoting effects of equol via up-regulation of eIF4GI and selective initiation of translation on mRNAs that utilize non-canonical initiation, including certain oncogenes PMID: 25593313
  12. Knockdown of eIF4GI was deleterious to myeloma cells phenotype and expression of specific molecular targets (SMAD5/ERalpha/HIF1alpha/c-Myc). PMID: 24815186
  13. Its mutation is not a common cause of familial Parkinson's disease. PMID: 24854799
  14. in a generic cell model, new insights into the mechanisms whereby the FSH receptor controls translation have been gained. Rapamycin-sensitive eIF4G phosphorylation at the 5' cap may be a surrogate for the classical exchange between eIF4G and 4E-BP1. PMID: 24711644
  15. The results of this study did not identify novel or previously reported pathogenic mutations (including the p.A502V and p.R1205H mutants) within EIF4G1 in the Japanese population. PMID: 24704100
  16. Data suggest that, in eIF4G/eif4A complex, eIF4G1 exhibits low-affinity ATP binding site in proximity of ATP-binding cleft of eif4A enhancing ATP binding; additional enhancement of eIF4G/eif4A binding is observed in crowded/intracellular environment. PMID: 25255371
  17. study revealed that the EIF4G1 R1205H and VPS35 D620N mutations were absent in 418 Parkinsoin Disease patients of various South African ethnic groups PMID: 24080171
  18. Report EIF4G binding within the IRES domain V of the coxsackie virus B3 mutant strain. PMID: 24063684
  19. Its mutation causes Parkinson's disease in Indian population. PMID: 23726718
  20. eukaryotic initiation factor 4G (eIF4G) protein binds to eIF3c, -d, and -e to promote mRNA recruitment to the ribosome. PMID: 24092755
  21. EIF4G1 mutations do not appear to play a role in patients with Parkinson disease from southwest China. PMID: 23261770
  22. The eIF4E-binding site in eukaryotic initiation factor 4G (eIF4G) functions as an autoinhibitory domain to modulate its ability to stimulate eIF4A helicase activity. PMID: 23901100
  23. The data of this study indicated that in an ethnic Chinese population, the pathogenic mutation p.R1205H in EIF4G1 is not common and that EIF4G1 exonic variants rs2178403 and rs13319149 are not associated with parkinson disease. PMID: 23617574
  24. The results suggest that in some patients variants in EIF4G1 can be associated with pathology that has a high likelihood of association with clinical features of dementia with Lewy bodies. PMID: 23124435
  25. the EIF4G1 p.Ala502Val and p.Arg1205His variants are a rare cause of PD, at least in Chinese population. PMID: 23562511
  26. In agreement with recent reports we conclude that convincing evidence establishes EIF4G1 mutations as a rare cause of Parkinson's disease PMID: 23490116
  27. eIF4GI participates in the miRNA-mediated post-transcriptional gene silencing by promoting the association of Ago2 with the cap-binding complex. PMID: 23409027
  28. EIF4G1 is an uncommon cause of PD in our Asian cohort. PMID: 23092605
  29. There is no evidence for an overall contribution of genetic variability in EIF4G1 (or VPS35) to Parkinson disease development in this large family. PMID: 23408866
  30. Results provide a mechanistic link between intracellular signal transduction and dynamic initiation complex formation coordinated by flexible eIF4G structure. PMID: 23263986
  31. Data show that eIF4G interacts with the RRM2 domain of polyadenylate-binding protein-1 (PABP). PMID: 23041282
  32. Increased expression of eIF4G1 therefore promotes specialized translation of survival, growth arrest, and DDR mRNAs that are important in cell survival and DNA repair following genotoxic DNA damage. PMID: 23112151
  33. EIF4G1 cDNAs, encoding different isoforms which arise through selection of alternative initiation codons, rescued translation from siRNA interference to different extents PMID: 22909319
  34. analysis of variants of eukaryotic translation initiation factor 4G1 in sporadic Parkinson\'s disease PMID: 22707335
  35. These data do not support the pathogenicity of several EIF4G1 variants in PD, at least in the French population. PMID: 22658323
  36. linkage analysis, mutations in EIF4G1 were implicated as a cause of Parkinson disease and mutations in SLC20A2 as a cause of familial idiopathic basal ganglia calcification. PMID: 22772876
  37. Found that either EIF4G1 variants are an extremely rare cause of familial Parkinson's Disease in Caucasian cohorts, or that A502V is in fact a rare benign variant not involved in Parkinson's Disease aetiology PMID: 22561553
  38. This finding demonstrates that viruses can increase host translation initiation factor concentration to foster their replication and defines a unique mechanism whereby control of PABP abundance regulates eIF4F assembly. PMID: 22431630
  39. The ssDNA-binding protein of Vaccinia virus, I3 interacts and co-localizes with the eIF4F scaffold protein, eIF4G inInfected cells. PMID: 22280895
  40. EIF4G1 mutations implicate mRNA translation initiation in familial parkinsonism. PMID: 21907011
  41. Data show that PKCalpha activation elicits a cascade of orchestrated phosphorylation events that may modulate eIF4G1 structure and control interaction with the eIF4E kinase, Mnk1. PMID: 21576361
  42. EIF4G1 can serve as a biomarker for the prognosis of nasopharyngeal carcinoma patients. PMID: 20398343
  43. HIV- 1 protease inhibits Cap- and poly(A)-dependent translation upon eIF4GI and PABP cleavage PMID: 19956697
  44. findings assign NAD(P)H quinone-oxydoreductase 1 an original role in the regulation of mRNA translation via the control of eIF4GI stability by the proteasome. PMID: 20028737
  45. mass spectrometric analysis of N terminus reveals novel isoforms PMID: 11821405
  46. demonstrate that the expression of the amino-terminal one-third of eIF4G, which interacts with eIF4E and PABP, in Xenopus oocyte inhibits translation and progesterone-induced maturation PMID: 11866104
  47. data suggest that expression of the eIF4GI isoforms is partly controlled by a complex translation strategy involving both cap-dependent and cap-independent mechanisms PMID: 12052860
  48. X-ray structure of rotavirus NSP3-C bound to the 30 residue fragment of eIF4G that is also recognized by poly(A) binding protein (PABP) PMID: 12086624
  49. proteolytic activity of HIV-1 protease on eIF4GI and eIF4GII and its implications for the translation of mRNAs PMID: 12505164
  50. Overexpression of EIF4G1 causes aberrant cell morphology and results in disruption of the localization of F-actin and the organization of microtubules. PMID: 12581158

Show More

Hide All

Involvement in disease
Parkinson disease 18 (PARK18)
Subcellular Location
Cytoplasm, Stress granule.
Protein Families
Eukaryotic initiation factor 4G family
Database Links

HGNC: 3296

OMIM: 600495

KEGG: hsa:1981

STRING: 9606.ENSP00000338020

UniGene: Hs.433750

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*